Victoza, a drug approved for the treatment of Type 2 diabetes, gained FDA approval in 2010 and was touted as an amazing new injectable diabetic drug which only required once-daily injections and was not dependent upon the food eaten or the level of activity. Over 26 million people in the United States are affected by diabetes therefore the market for diabetic drugs has literally skyrocketed. At the time Victoza was submitted by its manufacturer, Novo Nordisk, for FDA approval, there were two FDA pharmacologists and one FDA clinical safety reviewer who did not believe the drug warranted approval until further safety studies were conducted.